Wednesday, September 18, 2019 8:04:05 AM
8:00 AM ET 9/18/19 | PR Newswire
- U.S. patent supports the development and implementation of paired smartphone devices to collect and analyze real-time medical data
NEW YORK and CAESAREA, Israel, Sept. 18, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a leading, global digital therapeutics company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office titled "Systems and Methods for Enabling Optical Transmission of Data Between a Sensor and a Smart Device." The patent will allow Dario to develop paired smartphone devices that can collect and analyze real-time medical data and provide immediate and highly detailed, personalized data reports to the user. Once collected, this data can be shared with healthcare providers through the DarioEngage(TM) platform to facilitate digital health interventions based on the data analysis.
"Dario's business and product strategy is guided by evidence that shows that increased user engagement and direct empowerment of individuals to manage their personal health leads to better medical outcomes," said Erez Raphael, DarioHealth's chief executive officer. "As a result, our product innovation has continually focused on enhancing Dario's user experience and developing new ways to integrate intelligent, medical device technology with the smartphone to make health and chronic condition management easy, affordable and convenient."
DarioHealth's digital therapeutics solutions are unique in that they capture and analyze members' real-time, clinical data using a member's smartphone and allow for full access and connectivity to that data at any time throughout the day, along with personalized daily and weekly health data reports. This provides Dario members a fully personalized, integrated and exceptionally convenient platform to manage their health throughout the day, and facilitates a heightened user experience, increased user engagement and improved clinical health outcomes.
As the future of healthcare becomes increasingly digitized and focused on empowering individuals to take control of their personal health, DarioHealth believes smartphones will serve as the primary conduit for health interventions and chronic condition management.
As a pioneer in the digital therapeutics industry, DarioHealth supports the evolution of iOS and Android mobile devices and continually seeks opportunities to use smartphones as the primary health management device, integrated with connected medical devices, rather than requiring users to purchase and use a secondary device that has to synchronize information with a smartphone, which is less convenient, effective and efficient.
DarioHealth plans to begin development of new paired smartphone medical devices in the coming year, which will further advance the company's objective of providing highly effective, inexpensive and convenient digital therapeutic health solutions that empower individuals to best manage their chronic health conditions and improve their overall health.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://mydario.com/
Recent DRIO News
- Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes • PR Newswire (US) • 04/25/2024 12:30:00 PM
- Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health • PR Newswire (US) • 04/02/2024 12:30:00 PM
- DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH • PR Newswire (US) • 03/21/2024 12:30:00 PM
- New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications • PR Newswire (US) • 03/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:24:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:20:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:16:57 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/29/2024 09:03:08 PM
- DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE • PR Newswire (US) • 02/28/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:05:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:16:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/21/2024 09:09:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:30:08 PM
- Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions • PR Newswire (US) • 02/21/2024 11:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:31:35 PM
- Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET • GlobeNewswire Inc. • 01/22/2024 09:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/19/2024 09:15:52 PM
- Regional Union Selects Dario's Cardiometabolic Solution for Diabetes, Hypertension, Weight Management and GLP-1 Support • PR Newswire (US) • 01/11/2024 01:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM